强生今日宣布,旗下每六个月给药一次的长效针剂善久达®(棕榈帕利哌酮酯注射液 (6M),INVEGA HAFYERA®,英文通用名称:Paliperidone Palmitate Injection (6M))近日获得国家药品监督管理局上市许可批准,用于接受过棕榈帕利哌酮酯注射液 (3M) 至少3个月充分治疗的成人精神分裂症患者[1]。
参考文献:
[1] 棕榈帕利哌酮酯注射液(6M)说明书, 2024年6月.
[3] Najarian D, et al. A randomized, double-blind, multicenter, noninferiority study comparing Paliperidone Palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251.
[4] 国家卫生健康委. 精神障碍诊疗规范. 2020. P115.
[5] Xiao J, Mi W, Li L, Shi Y, Zhang H. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China. Neuropsychiatr Dis Treat. 2015 May 8. 11:1161-7.
[6] Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology. 2014. 4(5):198-219.
[7] Garcia-Portilla MP, et al. Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prespective study. Expert OpinPharmacother. 2022 Jan. 5:1-10.
[8] PungorK, et al. The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. BMC Psychiatry 2021 Jun. 21:300.
[9] Najarian D, et al. Long-term efficacy and safety of Paliperidone 6-month formulation: An open-lable 2-year extension of a 1-year double-blind study in adult participants with schizophrenia. Int J Neuropsychopharmacol. 2023 Jul 22. 26:537-544.